retatrutide oral drops Retatrutide Retatrutide Triple Agonist (GLP-1/GIP/GCG) |
Description
Jyrkas J, Tolonen A
~7% for tirzepatide in SURMOUNT-1) and a new dysesthesia signal at ~21% incidence that didn't appear in Phase 2
Davidson, V
An oral syringe under the tongue requires less fine motor control than a subcutaneous injection
These findings suggested that SGLT-2i may be causing hypotensive effects via the CNS, although its exact role is yet to be elucidated
LAMC1: laminin subunit gamma 1
